GRFS Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 106096 min ago

@ $8.53

Ausgestellt: 14 Feb 2024 @ 17:16

Rendite: -25.21%

Vorheriges Signal: Feb 13 - 18:31

Vorheriges Signal: Verkaufen

Rendite: 1.67 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

Stats
Tagesvolumen	673 301
Durchschnittsvolumen	2.14M
Marktkapitalisierung	5.23B
EPS	$0.140 ( 2024-03-05 )
Last Dividend	$0.456 ( 2021-06-03 )
Next Dividend	$0 ( N/A )
P/E	63.80
ATR14	$0.00700 (0.11%)

Volumen Korrelation

Lang: -0.07 (neutral)

Kurz: -0.05 (neutral)

Signal:(39.858) Neutral

Grifols S.A. Korrelation

10 Am meisten positiv korreliert
NETE	0.949
MMAC	0.937
TKNO	0.911
STRA	0.907
AMRB	0.897
VTRS	0.891
WLDN	0.89
TRUE	0.889
GRAB	0.887
HOLX	0.885

10 Am meisten negativ korreliert
SVAC	-0.951
PAIC	-0.935
RMRM	-0.93
SVOK	-0.91
TLGT	-0.906
MTSL	-0.873
CNET	-0.865
FTOC	-0.861
FVE	-0.857
FEYE	-0.854

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Grifols S.A. Korrelation - Währung/Rohstoff

0.30
( neutral )

0.56
( weak )

0.00
( neutral )

-0.40
( neutral )

Grifols S.A. Finanzdaten

Annual	2023
Umsatz:	$6.59B
Bruttogewinn:	$2.32B (35.24 %)
EPS:	$0.0873

FY	2023
Umsatz:	$6.59B
Bruttogewinn:	$2.32B (35.24 %)
EPS:	$0.0873

FY	2022
Umsatz:	$6.06B
Bruttogewinn:	$2.23B (36.80 %)
EPS:	$0.310

FY	2021
Umsatz:	$4.93B
Bruttogewinn:	$1.96B (39.78 %)
EPS:	$0.270

Financial Reports:

No articles found.

Grifols S.A. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Grifols S.A. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.88 - average (63.08%) | Divividend Growth Potential Score: 1.372 - No dividend growth expected in the near future

Information

First Dividend	$0.00650	2013-05-29
Last Dividend	$0.456	2021-06-03
Next Dividend	$0	N/A
Payout Date	2021-06-14
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	$3.04	--
Avg. Dividend % Per Year	0.38%	--
Score	1.9	--
Div. Sustainability Score	5.88
Div.Growth Potential Score	1.372
Div. Directional Score	3.63	--

Next Divdend (Est)
(2024-08-26)

$0 Estimate 0.00 %

Dividend Stability

0.07 Very Bad

Dividend Score

1.90

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2013	$0.136	1.06%
2014	$0.301	1.72%
2015	$0.353	2.05%
2016	$0.350	2.19%
2017	$0.375	2.33%
2018	$0.479	2.05%
2019	$0.394	2.18%
2020	$0.201	0.85%
2021	$0.456	2.41%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0251	1.500	9.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00769	1.200	9.74	10.00	[0 - 0.3]
returnOnEquityTTM	0.0279	1.500	-0.801	-1.202	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.79	0.800	1.069	0.855	[1 - 3]
quickRatioTTM	0.629	0.800	-1.006	-0.805	[0.8 - 2.5]
cashRatioTTM	0.229	1.500	9.84	10.00	[0.2 - 2]
debtRatioTTM	0.425	-1.500	2.92	-4.38	[0 - 0.6]
interestCoverageTTM	2.33	1.000	-0.248	-0.248	[3 - 30]
operatingCashFlowPerShareTTM	0.307	2.00	9.90	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.0538	2.00	-0.0269	-0.0538	[0 - 20]
debtEquityRatioTTM	1.564	-1.500	3.74	-5.62	[0 - 2.5]
grossProfitMarginTTM	0.381	1.000	6.99	6.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.135	1.000	9.30	9.30	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0229	1.000	-0.984	-0.984	[0.2 - 2]
assetTurnoverTTM	0.306	0.800	-1.291	-1.033	[0.5 - 2]
Total Score				5.88

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.55	1.000	7.62	0	[1 - 100]
returnOnEquityTTM	0.0279	2.50	-0.515	-1.202	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0538	2.00	-0.0179	-0.0538	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.307	2.00	9.90	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.413	1.500	-0.582	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0317	1.000	-1.708	0	[0.1 - 0.5]
Total Score				1.372

Grifols S.A.

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.